Anzeige
Mehr »
Login
Dienstag, 21.01.2025 Börsentäglich über 12.000 News von 682 internationalen Medien
Amazon investiert Millionen in Kernenergie - so können Sie sich früh positionieren!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A3DNYA | ISIN: SE0018040883 | Ticker-Symbol: 1FS0
Frankfurt
21.01.25
08:11 Uhr
4,200 Euro
0,000
0,00 %
Branche
Bau/Infrastruktur
Aktienmarkt
Sonstige
1-Jahres-Chart
FM MATTSSON AB Chart 1 Jahr
5-Tage-Chart
FM MATTSSON AB 5-Tage-Chart
RealtimeGeldBriefZeit
4,2004,40008:38
GlobeNewswire (Europe)
89 Leser
Artikel bewerten:
(0)

FM Mattsson Mora Group AB: Interim report January-March 2024

Finanznachrichten News

January-March 2024

  • Net sales were 493.4 MSEK (533.2), an decrease of 7.5% compared to the equivalent period in 2023. Organic growth was -8.0% for the period.
  • EBITA was 53.3 MSEK (78.5), an EBITA margin of 10.8% (14.7). Previous year was affected by one-off costs of 1.6 MSEK regarding an efficiency program in Sweden.
  • Earnings per share were 0.67 SEK (1.25).
  • Cash flow after investing activities was 38.3 MSEK (39.8).

Significant events during and after the quarter
No significant events have occurred during or after the end of the period.

STATEMENT FROM THE CEO

A mixed start to the year

Sales in the first quarter totalled SEK 493 million, 7.5% lower than the first quarter of 2023, which was particularly strong - our second highest ever. The EBITA margin was impacted by lower sales and amounted to 10.8% compared to 14.7% in the corresponding quarter in 2023. Cash flow has remained strong.

The market situation continues to be challenging for all business areas within the group. When we take a closer look at sales, we see mixed trends during the quarter. International sales have had a relatively good quarter, while the Nordic domestic market has been tougher. It is difficult to draw major conclusions from a single quarter, but we see advantages with our six brands that give us a better presence in different geographies and customer segments, and a better balance as a group with a more stable base. In the international market, we are still a small player in most countries, which provides greater scope for growth. Among our customers, we continue to see that it is primarily new construction and the more consumer-oriented businesses that show the least activity. Hopefully, we will see increased optimism in line with lower inflation and expected interest rate cuts. For the coming quarters, however, our assessment is that the economic situation will remain challenging.

Profitability in the quarter reduced, mainly as a result of lower sales. The gross margin was in line with last year thanks to changes in product mix and cost-effective purchasing for certain brands that compensated for the lower production volumes in the factory in Mora. We work continuously to adjust costs based on current production volumes and focus on initiatives that can improve cost efficiency in both the short and long term. We also have slightly higher overheads as a result of, among other things, our ongoing investments in enhancing our profile and market position, for example in the UK. Going forward, we will continue to work with a high level of cost awareness in all parts of the group in order to adapt to the development of demand in the best possible way.

In the longer term, we see a clear underlying need in all our countries to both renovate and build new bathrooms and kitchens. We are well positioned to meet that demand. The sale of new products that exude sustainable, attractive design is at the top of the agenda and we continue to develop our products further with that focus. During the quarter, Aqualla launched frames and cisterns to build into toilets and with so-called flush plates which match our taps. It is a completely new product category for us and it follows the strategy of Aqualla to offer an increasingly broad product range for bathrooms in the UK and Ireland. In parallel with the sales work, we are continuing to identify and implement cost efficiencies throughout the Group to balance the current economic situation. In summary, the year has begun with mixed results and signals in the market and we are addressing these with clear actions to enhance our marketing and internal efficiency.

For more information please contact:

Fredrik Skarp, CEO, Tel: +46 (0) 250 596 405.
Martin Gallacher, CFO, Tel +46 (0) 250 596 225.

About Us

FM Mattsson Group conducts the sale, manufacture and product development of water taps and related products under the strong, established brands of FM Mattsson, Mora Armatur, Damixa, Hotbath, Aqualla and Adamsez. The group's vision is to be the customer's first choice in the bathroom, kitchen and beyond. In 2023 the business generated sales of more than 1.9 billion SEK from its companies in Sweden, Norway, Denmark, Finland, Benelux, UK, Germany and Italy and had 568 employees. FM Mattsson Group is listed on Nasdaq Stockholm.

This information is information that FM Mattsson AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2024-05-07 08:00 CEST.

© 2024 GlobeNewswire (Europe)
Gewinner im Megamarkt
Biotechnologie ist eine der bedeutendsten Zukunftstechnologien unserer Zeit. Zahlreiche Biotechnologie- und Pharmakonzerne haben sich unter anderem dem Kampf gegen Tumorerkrankungen verschrieben. Der weltweite Markt für Krebsmedikamente verzeichnet ein stetiges Wachstum. Für das Jahr 2025 wird ein Umsatz von etwa 190,3 Milliarden Euro prognostiziert, mit einer erwarteten jährlichen Wachstumsrate von 6,42% bis 2029, was zu einem geschätzten Marktvolumen von 244,1 Milliarden Euro führen würde.

Wir haben 3 aussichtsreiche Biotechnologieaktien mit Schwerpunkt Erforschung und Entwicklung von Wirkstoffen gegen Tumorerkrankungen ausfindig gemacht, die in den kommenden Monaten und Jahren erhebliches Aufwärtspotenzial versprechen und Vervielfachungspotenzial besitzen.

Fordern Sie jetzt unseren neuen kostenlosen Spezialreport an und erfahren Sie, welche 3 Biotech-Aktien durchstarten und zu Ihrem Börsenerfolg in 2025 beitragen könnten!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.